SMAD specific E3 ubiquitin protein ligase 1 accelerates diabetic macular edema progression by WNT inhibitory factor 1

Figure 6 SMAD-specific E3 ubiquitin protein ligase 1 knockdown improved retinal damage in diabetic macular edema mice. A: The Streptozotocin (STZ) mouse model was constructed, and then the blood glucose concentration of the mice was examined; B: The STZ mouse model was constructed, and the permeability of mouse retinal blood vessels was then examined by Evans Blue assay; C: STZ model mice were injected intraocularly with adenoviruses of sh-NC or sh-SMAD-specific E3 ubiquitin protein ligase (SMURF) 1, and then the expression of SMURF1 was detected by quantitative real-time PCR; D: STZ model mice were injected intraocularly with adenoviruses of sh-NC or sh-SMURF1, and the expression of SMURF1 was then detected by western blot; E: STZ model mice were injected intraocularly with adenoviruses of sh-NC or sh-SMURF1, followed by western blot to detect the expression of occluding, ZO-1, and claudin-1; F: STZ model mice were injected intraocularly with adenoviruses of sh-NC or sh-SMURF1, and then the expression of Beclin-1, LC3I, LC3II, and p62 was detected by western blot; G: STZ model mice were injected intraocularly with adenoviruses of sh-NC or sh-SMURF1, followed by western blot to detect the expression of WIF1, Wnt1, β-catenin, and vascular endothelial growth factor was detected by western blot. n = 6. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. SMURF1: SMAD-specific E3 ubiquitin protein ligase 1; VEGF: Vascular endothelial growth factor; STZ: Streptozotocin.